<SEC-DOCUMENT>0001654954-20-000756.txt : 20200127
<SEC-HEADER>0001654954-20-000756.hdr.sgml : 20200127
<ACCEPTANCE-DATETIME>20200127090141
ACCESSION NUMBER:		0001654954-20-000756
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20200127
DATE AS OF CHANGE:		20200127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOSCIENCE, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-235695
		FILM NUMBER:		20547226

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>aytu_424b3.htm
<DESCRIPTION>424B3
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2020 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000">
<!--style header--><br></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Prospectus Supplement No. 3</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Filed Pursuant to Rule 424(b)(3)</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
File No. 333-235695</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 49%">
<div><img src="aytu_424b3000.jpg"></div>
</td>
<td style="vertical-align: top; width: 51%">
<div style="text-align: right"><img src="aytu_424b3001.jpg"></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Prospectus
Supplement No. 3 Dated January 27, 2020</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">To
Prospectus Dated January 15, 2020</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">This
prospectus supplement No.3 supplements the prospectus dated January
15, 2020 relating to the offering and sale by Aytu BioScience, Inc.
of shares of its common stock relating to the potential merger with
Innovus Pharmaceuticals, Inc. This prospectus supplement should be
read in conjunction with the prospectus which is to be delivered
with this prospectus supplement. Any statement contained in the
prospectus shall be deemed to be modified or superseded to the
extent that information in this prospectus supplement modifies or
supersedes such statement. Any statement that is modified or
superseded shall not be deemed to constitute a part of the
prospectus except as modified or superseded by this prospectus
supplement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">This
prospectus supplement is being filed to update and supplement the
information in the prospectus with a press release disseminated on
January 27, 2020</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Investing
in our common stock involves a high degree of risk. Before making
an investment decision, please read &#x201C;Risk Factors&#x201D;
beginning on page 26 of this prospectus.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Neither
the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of the securities to be
issued in connection with the transaction described in the
Prospectus or determined whether the Prospectus is truthful or
complete. Any representation to the contrary is a criminal
offense.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">This
date of this prospectus supplement is January 27, 2020</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 1px solid #000000; border-bottom: 4px solid #000000">
<!--style footer--><br></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
Aytu BioScience and Innovus Pharmaceuticals Announce Effectiveness
of Form S-4 Registration Statement Related to Proposed Acquisition
of Innovus by Aytu BioScience</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Aytu and Innovus Shareholder Meetings to Approve Merger Scheduled
for February 13, 2020</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">
ENGLEWOOD, CO &amp; SAN DIEGO, CA / ACCESSWIRE / January 27, 2020
/</font> Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty
pharmaceutical company focused on commercializing novel products
that address significant patient needs and Innovus Pharmaceuticals,
Inc. (OTCQB: INNV), a specialty pharmaceutical company
commercializing, licensing and developing safe and effective
consumer health products, today announced that the registration
statement on Form S-4 containing a joint preliminary proxy
statement/prospectus in connection with Aytu BioScience&#x2019;s
proposed acquisition of Innovus Pharmaceuticals is now effective
following the companies&#x2019; filing with the U.S. Securities and
Exchange Commission. With the effectiveness of Form S-4, Aytu and
Innovus have set their respective special shareholder meetings for
February 13, 2020 during which the companies&#x2019; shareholders
will vote on the merger agreement.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
registration statement containing the joint preliminary proxy
statement/prospectus is available through the SEC's website at
<font style="text-decoration: underline; color: #0563C1">www.sec.gov</font> and
on Aytu BioScience&#x2019;s website in the Investor
section.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Aytu BioScience special meeting is scheduled for February 13, 2020
at 10:00 AM Mountain Time. The meeting will be held at Aytu
BioScience&#x2019;s corporate headquarters, located at 373 Inverness
Parkway, Suite 206 Englewood, CO 80112.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Innovus Pharmaceuticals special meeting is also scheduled for
February 13, 2020 at 8:00 AM Pacific Time. The meeting will be held
at the Hyatt House San Diego, located at 10044 Pacific Mesa
Boulevard, San Diego, CA 92121.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">As
announced on September 12, 2019, the companies signed a definitive
merger agreement whereby Aytu will retire all outstanding common
stock of Innovus for an aggregate of up to $8 million in shares of
Aytu common stock, less certain deductions, at the time of closing,
including amounts owed from Innovus to Aytu under a promissory note
(currently $1.35 million principal amount), payments to be made to
warrant holders, changes in Innovus liabilities and working
capital, and other adjustments. This initial consideration to
Innovus common shareholders is currently estimated to consist of
approximately 3.8 million shares of Aytu stock. Each Innovus common
shareholder will also receive contingent value rights
(&#x201C;CVRs&#x201D;), representing the right to receive additional
consideration of up to an aggregate of $16 million, paid to in cash
or stock at Aytu&#x2019;s option, over the next five years if
certain revenue and profitability milestones are
achieved.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Innovus
generated over $24 million in revenue during the twelve-month
period ended December 31 2019 (unaudited) and has achieved the
initial revenue-based CVR milestone as specified in the merger
agreement. Upon finalization and audit of Innovus&#x2019; Q4 2019
revenue, Aytu expects to pay the $2M milestone payment. The
milestone payment is payable in stock or cash at the
company&#x2019;s option.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Through
this combined entity, Aytu will expand into the $40 billion
consumer healthcare market with a portfolio of over thirty-five
consumer products <font style="color: #000000">competing</font> in
large therapeutic categories including diabetes, men&#x2019;s
health, sexual wellness and respiratory health. This expanded
product line broadens Aytu&#x2019;s portfolio beyond prescription
therapeutics to enable wider revenue distribution, reduced
seasonality associated with Aytu&#x2019;s seasonal
antitussive/antihistamine product line, and higher revenue from an
expanded base of proprietary products.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Combined,
Aytu and Innovus products generated approximately $43 million in
revenue over the twelve-month period ended September 30, 2019. The
companies believe this business combination will provide increased
revenue scale and enable operational synergies that can be
leveraged to accelerate the combined company&#x2019;s growth and
path to profitability. Aytu will also take over the outstanding
notes payable of Innovus whichis expected to be approximately $3.2
million.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Upon
closing, Aytu expects to operate the commercial aspects of the
Innovus consumer business separately from Aytu&#x2019;s prescription
business, while rationalizing general and administrative expenses
through the removal of Innovus&#x2019; public company costs and
redundant administrative and operational processes, along with the
reduction in overhead, administrative and facilities
costs.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Aytu&#x2019;s
prescription product portfolio will continue to be primarily
commercialized through the existing Aytu sales force, while the
consumer health products will continue to be primarily
commercialized via Innovus&#x2019; proprietary Beyond Human&#xAE;
marketing platform. However, both lines of business are expected to
benefit from opportunistic cross-selling such that some consumer
products may be marketed in the physician office setting by
Aytu&#x2019;s sales force, while the marketing of the prescription
products may be bolstered through various online and
direct-to-consumer marketing initiatives.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">At the
time of signing the definitive agreement, Aytu had collected voting
agreements supporting the merger transaction that represent
approximately 35% of current shares outstanding. Innovus has thus
far collected voting agreements supporting the transaction that
represent approximately 24% of shares outstanding.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
acquisition is expected to close by February 14, 2020 if both
companies&#x2019; shareholders approve the transaction.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
About Aytu BioScience, Inc.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Aytu
BioScience is a commercial-stage specialty pharmaceutical company
focused on commercializing novel products that address significant
patient needs. The company currently markets a portfolio of
prescription products addressing large primary care and pediatric
markets. The primary care portfolio includes (i) Natesto&#xAE;, the
only FDA-approved nasal formulation of testosterone for men with
hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist&#x2122;,
the only FDA-approved oral spray prescription sleep aid, and (iii)
Tuzistra&#xAE; XR, the only FDA-approved 12-hour codeine-based
antitussive syrup. The pediatric portfolio includes (i)
AcipHex&#xAE; Sprinkle&#x2122;, a granule formulation of rabeprazole
sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor,
a second-generation cephalosporin antibiotic suspension; (iii)
Karbinal&#xAE; ER, an extended-release carbinoxamine
(antihistamine) suspension indicated to treat numerous allergic
conditions; and (iv) Poly-Vi-Flor&#xAE; and Tri-Vi-Flor&#xAE;, two
complementary prescription fluoride-based supplement product lines
containing combinations of fluoride and vitamins in various for
infants and children with fluoride deficiency. Aytu's strategy is
to continue building its portfolio of revenue-generating products,
leveraging its focused commercial team and expertise to build
leading brands within large therapeutic markets. For more
information visit aytubio.com.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
About Innovus Pharmaceuticals, Inc.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Headquartered
in San Diego, Innovus Pharmaceuticals is an emerging over the
counter (&#x201C;OTC&#x201D;) consumer goods and specialty
pharmaceutical company commercializing, licensing and developing
safe and effective non-prescription medicine and consumer care
products to improve men&#x2019;s and women&#x2019;s health and
vitality. The Company is dedicated to being a leader in developing
and marketing new OTC medicines and branded Abbreviated New Drug
Application (&#x201C;ANDA&#x201D;) products. The Company is actively
pursuing opportunities where existing prescription drugs have
recently, or are expected to, change from prescription to
OTC.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
No Offer or Solicitation</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Communications
in this news release do not constitute an offer to sell or the
solicitation of an offer to buy any securities or a solicitation of
any vote or approval with respect to the proposed transaction or
otherwise, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. Communications in this
news release do not constitute a notice of redemption with respect
to or an offer to purchase or sell (or the solicitation of an offer
to purchase or sell) any security of Innovus.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Additional Information and Where to Find It</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
connection with the proposed transaction between Aytu and Innovus,
Aytu and Innovus will file relevant materials with the Securities
and Exchange Commission (the &#x201C;SEC&#x201D;), including an Aytu
registration statement on Form S-4 that will include a joint proxy
statement of Aytu and Innovus that also constitutes a prospectus of
Aytu, and a definitive joint proxy statement/prospectus will be
mailed to shareholders of Aytu and Innovus. INVESTORS AND SECURITY
HOLDERS OF AYTU AND INNOVUS ARE URGED TO READ THE JOINT PROXY
STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH
THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and
security holders will be able to obtain free copies of the
registration statement and the joint proxy statement/prospectus
(when available) and other documents filed with the SEC by Aytu or
Innovus through the website maintained by the SEC at
http://www.sec.gov. Copies of the documents filed with the SEC by
Aytu will be available free of charge on Aytu&#x2019;s internet
website at https://irdirect.net/AYTU under the heading &#x201C;SEC
Filings&#x201D; or by contacting Aytu&#x2019;s investor relations
contacts at (646) 755-7412 or james@haydenir.com. Copies of the
documents filed with the SEC by Innovus will be available free of
charge on Innovus&#x2019; internet website at
https://innovuspharma.com/Investors/ under the heading &#x201C;SEC
Filings&#x201D; or by contacting Innovus&#x2019; investor relations
at ir@innovuspharma.com.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Certain Information Regarding Participants</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Aytu,
Innovus, and their respective directors and executive officers may
be considered participants in the solicitation of proxies in
connection with the proposed transaction. Information about the
directors and executive officers of Aytu is set forth in its Annual
Report on Form 10-K for the year ended June 30, 2019, which was
filed with the SEC on September 26, 2019. Information about the
directors and executive officers of Innovus is set forth in its
Annual Report on Form 10-K for the year ended December 31, 2018,
which was filed with the SEC on April 1, 2019 and its proxy
statement for its 2019 annual meeting of shareholders, which was
filed with the SEC on April 30, 2019. Other information regarding
the participants in the proxy solicitations and a description of
their direct and indirect interests, by security holdings or
otherwise, will be contained in the joint proxy
statement/prospectus and other relevant materials to be filed with
the SEC regarding the proposed transaction when they become
available. You may obtain these documents (when they become
available) free of charge through the website maintained by the SEC
at http://www.sec.gov and from Investor Relations at Aytu or
Innovus as described below.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Forward-Looking Statements</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">This
press release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, or the
Exchange Act. Forward-looking statements are generally written in
the future tense and/or are preceded by words such as ''may,''
''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,''
''suggest,'' ''believe,'' ''estimate,'' ''continue,''
''anticipate,'' ''intend,'' ''plan,'' or similar words, or the
negatives of such terms or other variations on such terms or
comparable terminology. All statements other than statements of
historical facts contained in this presentation, are
forward-looking statements, including but not limited to any
statements regarding the expected timetable for completing the
proposed transaction, the results, effects, benefits and synergies
of the proposed transaction, future opportunities for the combined
company, future financial performance and condition, guidance and
any other statements regarding Aytu&#x2019;s or Innovus&#x2019;
future expectations, beliefs, plans, objectives, financial
conditions, assumptions or future events or performance. These
statements are just predictions and are subject to risks and
uncertainties that could cause the actual events or results to
differ materially. These risks and uncertainties include, among
others: failure to obtain the required votes of Innovus&#x2019;
shareholders or Aytu&#x2019;s shareholders to approve the
transaction and related matters, the risk that a condition to
closing of the proposed transaction may not be satisfied, that
either party may terminate the merger agreement or that the closing
of the proposed transaction might be delayed or not occur at all,
the price per share utilized in the formula for the initial $8
million merger consideration may not be reflective of the current
market price of Aytu&#x2019;s common stock on the closing date, the
failure to meet the revenue and profitability milestones that
trigger the CVRs such that Innovus shareholders never realize value
from the CVRs, potential adverse reactions or changes to business
or employee relationships, including those resulting from the
announcement or completion of the transaction, the diversion of
management time on transaction-related issues, the ultimate timing,
outcome and results of integrating the operations of Aytu and
Innovus, the effects of the business combination of Aytu and
Innovus, including the combined company's future financial
condition, results of operations, strategy and plans, the ability
of the combined company to realize anticipated synergies in the
timeframe expected or at all, changes in capital markets and the
ability of the combined company to finance operations in the manner
expected, regulatory approval of the transaction, risks relating to
gaining market acceptance of our products, obtaining reimbursement
by third-party payors, the potential future commercialization of
our product candidates, the anticipated start dates, durations and
completion dates, as well as the potential future results, of our
ongoing and future clinical trials, the anticipated designs of our
future clinical trials, anticipated future regulatory submissions
and events, our anticipated future cash position and future events
under our current and potential future collaboration. We also refer
you to the risks described in ''Risk Factors'' in Part I, Item 1A
of the company's Annual Report on Form 10-K and in the other
reports and documents we file with the Securities and Exchange
Commission from time to time.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 62%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Contact for AYTU Investors:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 38%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Contact for INNV Investors:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 62%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">James
Carbonara</font></div>
</td>
<td style="vertical-align: top; width: 38%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Randy
Berholtz</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 62%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Hayden
IR</font></div>
</td>
<td style="vertical-align: top; width: 38%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Innovus
Investor Relations</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 62%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><a name="_Hlk18698307"><!--anchor--></a>(646) 755-7412</font></div>
</td>
<td style="vertical-align: top; width: 38%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(858)
249-7865</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 62%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">james@haydenir.com</font></div>
</td>
<td style="vertical-align: top; width: 38%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">ir@innovuspharma.com</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>aytu_424b3000.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 aytu_424b3000.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !. /8# 2(  A$! Q$!_\0
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M3^\7AQ7'-SQ6YX=AD\V2;)$>-N/[QK3(J]2&)4(JZ>_^9QXZ$72YGNCI*0D
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M3XB>&#X:\1N84Q8W9,L''"GNOX?RKLPM6WN,\G,<,I+G2]3/M;A+QU6+[['
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MU*QTOQQ//J%W#:PFT==\SA5SD<9-?1W_  F_A;_H8=-_\"5_QH WZ\Y^.?\
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1#;Z='&XBW[C&O3(&** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>aytu_424b3001.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 aytu_424b3001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M -8# 2(  A$! Q$!_\0
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MAT1_PF^JXYRK<_\  J]2N;:&]MI+>XC$D,B[71NA%<OX+\&GPSY\]Q.L]W,
MK,H(51UP,^];NO6MU?:'=VME-Y-S)'MCDSC::G$SC.M[K[:CPT)4Z/O+770Y
M";X3:.\S/%=7,:$\)PV/;FF?\*CTK@_;KGC_ &5K/'@GQI@?\3U?^_K4O_"$
M^-/^@\/^_K5U\TO^?R.7EA_SY9SGB;05\(:Q'!97DNV6'=N!VL.>AQ1736GP
MQU"[NWFUO5!)E,*4RS9SWSVZT5UPQF&C&U1\S[V.2>#Q$I7IKE7:YZ?1117@
M'T 4444 %%%% !1110 4444 ,DBCE7;(BNN<X89&:R;GP]9/J#ZC%"OVW[RL
MQ.W=V)%;-)CFI<(R:;6Q2G.*:BVKG'7O@*WUG5+;5=1N&6Z4#STAX20CH>>E
M=):::EI>7-RLTKM<;=RNV57 QP.U7J*.6-[B3:CRW"BBBJ$4M3U*'2[7SY@S
M*6"@(,DD]*H2>)$A1I)M/OXXU&69H3@"F>+HO-TF(;MI^TQX..G-/FT*[N8'
MAGUFX>)QM91&HR/K7)4E6YW&'Z'73A24(RGU;[^1<M]7MKJ^^RQ%B_D+/G'!
M4]*?=ZE!9W-O!)NWW!(3 XX]:P5T:"3Q.]MYDJ1PV:!=CE3P<<D4:AHT5IJF
MFO'/.V9&!$DA;M[UFZU90;MLRO84N=*^ZO\ @:*>(8IMS6]G=S1JQ7?''D$C
MK2'Q/9+9FXV3';-Y#)L^8/Z8JGH.ERRZ:LBZC=1!I&.Q"N!R?:LN2Q/V:XA,
M[$G6%'F8^;ZUG.O6C!2[W-(4*,IN/8WY/$D4*M)-87T42_>D> @"K":]8OJB
MV&_$CQAT8]&R,@"L&:QN&U?^S+S4KFX@F&>"%X]#US^E/?18;SQ'?6Q<H$M8
MO*91S&1T(I^WK7LN]A>PHVN^U]#J+BYBM+=YYW"1H,DGM66OB:S>WMYHXYI#
M<$B.-$RQQU-9%CY^OW)M[Z8-#9 Y0+Q*PZ,W/Z5#IMBTTNE(+AXR#.0R#!%)
MXR4Y+DV?_ ''!Q@FJFZ_R;_0WW\1V]O@W-K=P*>C/%P3Z45E>(]+DBL8F;4;
=J4>9C$FT@<'T%%88C'5Z-1PLCHPV"H5J?.VS_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
